Baird Courtney E, Myers Evan, Jacoby Vanessa, Gressler Laura Elisabeth, Venable Sateria, O'Neill Allison, Price Veronica, Lee Angie, Roberts Jason, Andrews Sharon, Sedrakyan Art, Marinac-Dabic Danica
Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island, USA.
Population Health Sciences, Weill Cornell Medicine, New York, New York, USA.
BMJ Surg Interv Health Technol. 2022 Nov 11;4(Suppl 1):e000094. doi: 10.1136/bmjsit-2021-000094. eCollection 2022.
The accumulation of data through a prospective, multicenter coordinated registry network (CRN) is a robust and cost-effective way to gather real-world evidence on the performance of uterine fibroids treatment technologies for device-based and intervention-based studies. To develop the CRN, a group of uterine fibroids experts, consisting of representatives from professional societies, the US Food and Drug Administration, academia, industry, and the patient community, was convened to discuss the role and feasibility of the CRN and to identify the core data elements needed to assess uterine fibroid treatment technologies.
A Delphi method approach was employed to achieve consensus on a core minimum data set for the CRN. A series of surveys were sent to the panel and answered by each expert anonymously and individually. Results from the surveys were collected, collated, and analyzed by a study design team from Weill Cornell Medicine. Questions for the next round were based on the analysis process and discussed with group members via a conference call. This process was repeated twice over a 3-month time period until consensus was achieved.
Twenty-nine experts participated in the Delphi surveys, which began with an initial list of 200 data elements. The working group reached final consensus on 97 data elements capturing patient medical history, imaging data, procedure-related data, post-procedure data, and long-term follow-up data.
The CRN successfully convened an expert panel on uterine fibroids treatment technologies and used the Delphi method to produce a consensus-based core set of data elements. These identified data elements include important outcomes related to efficacy and safety and thus, influence patient, provider, and regulatory decision-making about treatments for uterine fibroids. Finally, the core data elements provide the foundation of the infrastructure needed for the CRN that will allow for the comparative study of uterine fibroid treatment devices and technologies.
通过前瞻性多中心协调注册网络(CRN)积累数据,是一种强有力且具有成本效益的方式,可用于收集有关子宫肌瘤治疗技术在基于设备和基于干预研究中的真实世界证据。为了建立CRN,召集了一组子宫肌瘤专家,成员包括专业协会、美国食品药品监督管理局、学术界、行业和患者群体的代表,以讨论CRN的作用和可行性,并确定评估子宫肌瘤治疗技术所需的核心数据元素。
采用德尔菲法就CRN的核心最小数据集达成共识。向专家小组发送了一系列调查问卷,每位专家匿名单独作答。威尔康奈尔医学院的研究设计团队收集、整理和分析了调查结果。下一轮的问题基于分析过程,并通过电话会议与小组成员进行讨论。在3个月的时间内重复此过程两次,直至达成共识。
29位专家参与了德尔菲调查,最初列出了200个数据元素。工作组就97个数据元素达成了最终共识,这些数据元素涵盖患者病史、影像数据、手术相关数据、术后数据和长期随访数据。
CRN成功召集了一个关于子宫肌瘤治疗技术的专家小组,并使用德尔菲法得出了基于共识的核心数据元素集。这些确定的数据元素包括与疗效和安全性相关的重要结果,因此会影响患者、医疗服务提供者以及监管机构对子宫肌瘤治疗的决策。最后,核心数据元素为CRN所需的基础设施奠定了基础,这将有助于对子宫肌瘤治疗设备和技术进行比较研究。